Biomarker Discovery for IBD

The current gold standard for identifying and following the course of IBD is colonoscopy. Yet the invasive nature and expense of endoscopy mean it cannot be used routinely to monitor disease activity in patients with IBD. The focus on deploying biomarkers to improve disease surveillance and therapy is therefore increasingly needed. We can extract biomarkers from blood, tissues, stool. There are some things you'd want in a biomarker – it must be easy to sample, reproducible, and should be specific to the disease being studied.

Fig. 1. Discovering the lBD molecular biomarkers. Fig. 1. The current status of molecular biomarkers for inflammatory bowel disease. (Alghoul et al., 2022)

Our Biomarker Discovery Services

At Ace Therapeutics, we have a preclinical contract research provider team focused on biomarker discovery for IBD. We help our clients to find biomarkers of IBD using cutting-edge multi-omics technologies. We provide data bolsters all of these, from diagnosis severity of disease, therapeutic response predictions, and to endoscopic and histological healing and risk of recurrence.

We have cultivated bespoke biomarker service capabilities, tailored to accommodate an array of diverse research initiatives. If your specific biomarker needs aren't reflected below, we'll do our utmost to customize a solution tailored to your unique requirements.

Biomarkers You May Be Interested In

Serum biomarkers	C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR), Cytokines, Non-coding RNAs (ncRNAs), Extracellular matrix (ECM) components, Growth factors, Trefoil factor 3 (TFF3), Gelsolin, Oncostatin M (OSM), Serum metabolites, Matrix metalloproteinase (MMP), Amyloid A (SAA)
Serological biomarkers	Anti-Saccharomyces cerevisiae antibodies (ASCA), Anti-chitobioside carbohydrate antibodies (ACCA), Anti-laminaribioside carbohydrate antibodies (ALCA), Anti-laminarin antibodies (Anti-L), Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), Antibodies against exocrine pancreas (PABs), Antibodies to goblet cells (GAB)
Fecal biomarkers	Calprotectin, Calgranulin C, Lactoferrin, Lipocalin-2, Fecal high mobility group box 1 (HMGB1), Hemoglobin
Urine biomarkers	Citric acid cycle intermediates, Butyrate, Phenylacetate, Hippurate, Carbonic anhydrase 1, Neutrophil collagenase, Neutrophil gelatinase-associated lipocalin, Beta-mannosidase

Our Biomarker Technology Platforms

biomarker-discovery-for-ibd-2

Sample Types (Platform-Specific Analysis Available)

Whole blood	Serum	Plasma
Feces	Urine	Genomic DNA
Colon tissue	Cells	-

Integrating Biomarker Discovery in IBD Drug Development

Ace Therapeutics works on biomarker discovery at all stages of drug development, from disease identification, through disease monitoring and progression, and evaluation of the safety and efficacy of new therapeutics for IBD.

Enhanced Drug Target Selection

Biomarkers play a crucial role in elucidating the biological pathways associated with IBD. By analyzing these markers, we help clients identify potential drug targets most relevant to the underlying mechanisms of IBD.

Building Better Biofluid Biomarkers

Biomarkers can be measured in a matrix of liquid biosamples, increasing accessibility and recurrence, and convenience of sampling.

Indications of Drug Mode of Action

Integrating biomarker data allow us to provide insights into the mode of drug action, revealing how it interacts with specific pathways involved in IBD.

Monitoring Drug Response

Our Biomarker analysis enables researchers to test the safety and efficacy of IBD drugs.

Ace Therapeutics biomarker discovery tools allow you to discover new biomarker candidates for a diagnostic and treatment IBD breakthrough. If you have any queries then you can reach out to us. Let's work together.

Reference

Alghoul, Z., et al. (2022). The current status of molecular biomarkers for inflammatory bowel disease. Biomedicines, 10(7), 1492.

! For research use only, not intended for any clinical use.